Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of Health Catalyst Inc (NASDAQ: HCAT) was $2.83 for the day, down -23.31% from the previous closing price of $3.69. In other words, the price has decreased by -$23.31 from its previous closing price. On the day, 3.21 million shares were traded. HCAT stock price reached its highest trading level at $3.2098 during the session, while it also had its lowest trading level at $2.8.
Ratios:
Our analysis of HCAT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.81 and its Current Ratio is at 1.81. In the meantime, Its Debt-to-Equity ratio is 0.50 whereas as Long-Term Debt/Eq ratio is at 0.48.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 05 ’25 when Landry Benjamin sold 6,057 shares for $3.94 per share. The transaction valued at 23,891 led to the insider holds 151,125 shares of the business.
BENJAMIN LANDRY bought 6,057 shares of HCAT for $23,925 on Jun 05 ’25. On Jun 02 ’25, another insider, Benjamin Landry, who serves as the Officer of the company, bought 3,255 shares for $3.63 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HCAT now has a Market Capitalization of 198856736 and an Enterprise Value of 274608352. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.62 while its Price-to-Book (P/B) ratio in mrq is 0.57. Its current Enterprise Value per Revenue stands at 0.869 whereas that against EBITDA is -15.339.
Stock Price History:
The Beta on a monthly basis for HCAT is 1.54, which has changed by -0.5550314 over the last 52 weeks, in comparison to a change of 0.19554341 over the same period for the S&P500. Over the past 52 weeks, HCAT has reached a high of $9.24, while it has fallen to a 52-week low of $3.48. The 50-Day Moving Average of the stock is -26.27%, while the 200-Day Moving Average is calculated to be -46.84%.
Shares Statistics:
HCAT traded an average of 559.20K shares per day over the past three months and 833060 shares per day over the past ten days. A total of 70.27M shares are outstanding, with a floating share count of 66.05M. Insiders hold about 5.11% of the company’s shares, while institutions hold 81.04% stake in the company. Shares short for HCAT as of 1752537600 were 3741056 with a Short Ratio of 6.69, compared to 1749772800 on 3237510. Therefore, it implies a Short% of Shares Outstanding of 3741056 and a Short% of Float of 6.140000000000001.
Earnings Estimates
The current assessment of Health Catalyst Inc (HCAT) involves the perspectives of 7.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $0.11, with high estimates of $0.14 and low estimates of $0.09.
Analysts are recommending an EPS of between $0.27 and $0.22 for the fiscal current year, implying an average EPS of $0.23. EPS for the following year is $0.41, with 11.0 analysts recommending between $0.62 and $0.29.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 3 analysts. It ranges from a high estimate of $75M to a low estimate of $74.91M. As of the current estimate, Health Catalyst Inc’s year-ago sales were $76.35MFor the next quarter, 3 analysts are estimating revenue of $74.57M. There is a high estimate of $74.87M for the next quarter, whereas the lowest estimate is $74M.
A total of 11 analysts have provided revenue estimates for HCAT’s current fiscal year. The highest revenue estimate was $335M, while the lowest revenue estimate was $309.89M, resulting in an average revenue estimate of $325.47M. In the same quarter a year ago, actual revenue was $306.58MBased on 12 analysts’ estimates, the company’s revenue will be $346.14M in the next fiscal year. The high estimate is $369.75M and the low estimate is $301.97M.
